Celcuity Inc. at Citi Biopharma Back to School Summit Transcript
Everyone, and welcome to Citi's back-to-school biopharma summit. I'm Eric Joseph, senior biotech analyst with the firm. And one of our first fireside sessions this morning is with CellQuity, and it's my pleasure to be joined by company CEO, Brian Sullivan, to discuss the company. So Brian, thanks for joining us.
You're welcome. No, thanks for having me.
Maybe for anyone less familiar with the company, Brian, it would be.
We could perhaps have you start out by just providing some high-level remarks, and then we'll hop into Q&A.
Sure. So our lead candidate is actually now an approved drug, Revtropic, which is a Pan-PI3K mTORC1/2 inhibitor. And we recently received approval for a second-line indication in HR-positive HER2-negative advanced breast cancer.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
